# Azithromycin Treatment for the Airway Microbiome in Asthma

> **NCT03736629** · PHASE2 · TERMINATED · sponsor: **University of Chicago** · enrollment: 17 (actual)

## Conditions studied

- Asthma Chronic

## Interventions

- **DRUG:** Azithromycin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03736629
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-01
- **Primary completion:** 2021-03-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Inability to accrue patients, particularly after COVID pandemic.
- **Last updated:** 2023-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03736629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03736629, "Azithromycin Treatment for the Airway Microbiome in Asthma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03736629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*